Levodopa or short-acting dopamine (DA) agonist treatment of advanced parkinsonian patients exposes striatal DA receptors to non-physiologic intermittent stimulation that contributes to the development of dyskinesias and other motor complications. To determine whether continuous dopaminergic stimulation can delay or prevent onset of motor complications, four MPTP-lesioned, levodopa-naive cynomol...

Auditory event related potentials (ERPs) and visual evoked potentials (VEPs) were recorded from eight patients with Parkinson's disease, before and after a single dose of apomorphine. To assess the treatment effects, the patients' motor state, Benton visual retention test (BVRT), and digit span tests were also examined. After apomorphine, although motor performance improved, the ERP latencies w...

background: therapeutic effects of lithium in manic-depressive disorders have been clarified. during the present study, the effects of lithium carbonate have been assessed on apomorphine-induced sniffing in rats. materials and methods: male albino rats were housed in a glass cylinder and food and water were freely available till 60 minutes before the experiment. immediately after apomorphine in...

A constant pressure perfusion of the sinus node artery was performed in 10 in situ and in 3 isolated SA node preparations. The selective administration of apomorphine caused a negative chronotropic effect which was not blocked by treatment with atropine. The sinus deceleration was usually produced by apomorphine, 10-300 mug, while sinus irregularity and finally atrioventricular nodal rhythm in ...

OBJECTIVES To determine whether continuous waking day dopaminergic stimulation with the dopamine agonist apomorphine can reduce levodopa induced dyskinesias in Parkinson's disease METHODS 19 patients with severe unpredictable refractory motor fluctuations and functionally disabling levodopa induced dyskinesias were treated with continuous subcutaneous apomorphine monotherapy for a minimum dur...

1 Increases in renal blood flow were produced by intra-arterial injections of dopamine (5-50 mug) in anaesthetized dogs pretreated with alpha- and beta-adrenoceptor antagonists.2 Intra-arterial administration of ergometrine (0.5 mg) or apomorphine (1 mg) produced a depression of the renal dilator responses to dopamine, without affecting renal dilatations in response to intra-arterial acetylchol...

The alterations in local cerebral glucose utilisation in eight discrete nuclei in the thalamus following the administration of apomorphine (0.5 mg kg-1) have been investigated with the autoradiographic 2-deoxyglucose technique in 11 conscious rats. In two thalamic nuclei (parafascicular and ventrolateral nuclei), glucose utilisation was significantly elevated following apomorphine; in two thala...

BACKGROUND Parkinson disease (PD) is often difficult to distinguish from parkinsonian syndromes of other causes in early stages of the disease. In search of a suitable endocrinologic challenge test, we investigated dopaminergic sensitivity in patients with de novo parkinsonian syndromes. OBJECTIVE We measured the growth hormone (GH) response to a subthreshold dose of the dopamine 1-dopamine 2...

Apomorphine, now established as an efficacious therapy for refractory motor fluctuations in levodopa-treated Parkinson's disease, has a long and chequered history in medical and veterinary therapeutics. The preclinical in vivo pharmacological effects of apomorphine were first studied about 150 years ago following which the drug was introduced for the treatment of behavioural vices in domesticat...